Pioneering Studies Provide New Options for Patients with Advanced Cancers   
Make an Appointment

Pioneering Studies Provide New Options for Patients with Advanced Cancers

What You Need to Know

Researchers from Hackensack Meridian John Theurer Cancer Center are presenting data from 29 studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO). Abstracts of the studies can be viewed at

Some of the Key Presentations:

  • In acute myeloid leukemia (AML): A great trial building up on the success of Vyxeos (dual-drug liposomal encapsulation of daunorubicin and cytarabine) adding in the V-FAST multicenter trial a number of established targeted agents (midostaurin, venetoclax, enasidenib). Though preliminary, this is a great approach to refine the induction of AML and will be presented by Dr James McCloskey. (
  • CAR T cell update: With the three year follow up of ZUMA-2, the 1st CAR T approved in mantle cell – showing that brexucabtagene autoleucel (KTE-X19) which led to an ORR of 91%, with a 68% CR rate in heavily pretreated MCL pts and at 3 years 37% of pts still in ongoing response (all CR) and results were even better in patients who tested MRD-ve with medians for DOR, PFS, and OS  not reached at 3y. (
  • An update on ZUMA-7, which confirmed the benefit of Axi-cel (over standard of care) and its approval in April 2022 as a 2nd line therapy in relapsed/refractory diffuse large cell lymphoma, including in the population over 65 years old with significantly superior CR rate, EFS as well as meaningful improvement in QoL over SOC, measured by multiple validated PRO instruments.(
  • Other data on CAR T include CAR T combinations to improve outcome in diffuse large cell lymphoma such as the ZUMA-14 trial. (

Additional abstracts of which JTCC took part in the development of novel emerging agents in lymphoma, CLL, myeloma and solid tumors can be found here.  

We use cookies to improve your site experience. By using this site,
you agree to our Terms & Conditions. Also, please read our Privacy Policy. Accept All CookiesLearn More